文献速递妇科

美国低级别浆液性卵巢癌新辅助化疗使用趋势

Trends in the use of neoadjuvant chemotherapy for low-grade serous ovarian cancer in the United States.
PubMed 文献 · Gynecol Oncol · 2023-06-14

研究分析了2004年至2020年间美国癌症委员会认证项目中3350例III或IV期低级别浆液性卵巢癌患者,发现新辅助化疗使用比例从9.5%升至25.9%,年变化百分比7.2%。高龄和IV期疾病与新辅助化疗可能性更高相关。在高grade疾病中,新辅助化疗与肠道或泌尿手术可能性降低相关,而在低级别浆液性卵巢癌中则与更高可能性相关。

要点

  • 低级别浆液性卵巢癌新辅助化疗使用从2004年9.5%增至2020年25.9%,年变化百分比7.2%。
  • 高龄(RR 1.15)和IV期(RR 2.66)与接受新辅助化疗可能性更高相关。
  • 低级别浆液性卵巢癌接受新辅助化疗者肠道或泌尿手术比例更高(32.2% vs 26.6%,RR 1.24)。

核心结论

  • 低级别浆液性卵巢癌患者新辅助化疗使用从2004年至2020年增加。
  • 在高grade疾病中,新辅助化疗与肠道或泌尿手术可能性降低相关;而在低级别浆液性卵巢癌中,接受新辅助化疗者更可能接受这些手术。

研究设计与样本

  • 研究纳入2004年1月至2020年12月间在癌症委员会认证项目中治疗的III或IV期浆液性卵巢癌女性。
  • 使用回归模型评估低级别浆液性卵巢癌新辅助化疗趋势、与新辅助化疗相关的因素及其与手术时肠或泌尿切除的关联,并控制人口学和临床混杂因素。
  • 研究期间观察到3350例接受治疗的低级别浆液性卵巢癌患者。

主要发现

  • 接受新辅助化疗的患者比例从2004年的9.5%增加至2020年的25.9%,年变化百分比为7.2%(95%CI 5.6-8.9)。
  • 年龄增长(RR 1.15;95%CI 1.07-1.24)和IV期疾病(RR 2.66;95%CI 2.31-3.07)与接受新辅助化疗可能性更高相关。
  • 在高grade疾病患者中,新辅助化疗与肠或泌尿手术可能性降低相关(35.3% vs 23.9%;RR 0.68,95%CI 0.65-0.71)。
  • 在低级别浆液性卵巢癌中,新辅助化疗与这些手术可能性更高相关(26.6% vs 32.2%;RR 1.24,95%CI 1.08-1.42)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To describe trends in neoadjuvant chemotherapy (NACT) use for low-grade serous ovarian carcinoma (LGSOC) and to quantify associations between NACT and extent of cytoreductive surgery. METHODS: We identified women treated for stage III or IV serous ovarian cancer in a Commission on Cancer accredited program between January 2004-December 2020. Regression models were developed to evaluate trends in NACT use for LGSOC, to identify factors associated with receipt of NACT, and to quantify associations between NACT and bowel or urinary resection at the time of surgery. Demographic and clinical factors were used for confounder control. RESULTS: We observed 3350 patients who received treatment for LGSOC during the study period. The proportion of patients who received NACT increased from 9.5% in 2004 to 25.9% in 2020, corresponding to an annual percent change of 7.2% (95% CI 5.6-8.9). Increasing age (rate ratio (RR) 1.15; 95% CI 1.07-1.24), and stage IV disease (RR 2.66; 95% CI 2.31-3.07) were associated with a higher likelihood of receiving NACT. For patients with high-grade disease, NACT was associated with a decrease in likelihood of bowel or urinary surgery (35.3% versus 23.9%; RR 0.68, 95% CI 0.65-0.71). For LGSOC, NACT was associated with a higher likelihood of these procedures (26.6% versus 32.2%; RR 1.24, 95% CI 1.08-1.42). CONCLUSION: NACT use among patients with LGSOC has increased from 2004 to 2020. While NACT was associated with a lower rate of gastrointestinal and urinary surgery among patients with high-grade disease, patients with LGSOC receiving NACT were more likely to undergo these procedures.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Silberman JN, Bercow AS, Gockley AA, et al. Trends in the use of neoadjuvant chemotherapy for low-grade serous ovarian cancer in the United States. Gynecol Oncol. 2023. PMID: 37327540. doi:10.1016/j.ygyno.2023.06.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。